# Olmesartan as an add-on to Amlodipine in Hypertension

> **NCT00220233** · PHASE3 · COMPLETED · sponsor: **Sankyo Pharma Gmbh** · enrollment: 632 (—)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil
- **DRUG:** amlodipine
- **DRUG:** hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00220233
- **Lead sponsor:** Sankyo Pharma Gmbh
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 632 (—)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220233, "Olmesartan as an add-on to Amlodipine in Hypertension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00220233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*